***Background.*** Antimicrobial stewardship programs (ASPs) are an effective strategy to ensure that antimicrobial (AM) agents are used in accordance with scientific evidence to improve patient outcome, reduce the unnecessary use of AM and costs. We report the impact of the implementation of an ASP on AM use and pharmacy costs among hospitalized children

***Methods.*** In March 2012, active surveillance of AM therapy was implemented Vanderbilt Children\'s Hospital using Sentri7 (Pharmacy One Source®). Automated rules were developed to identify patients on broad-spectrum antibiotics and antifungals, acyclovir, therapeutic duplication, and with bug-drug mismatches. Dashboards were reviewed by an infectious disease pharmacist and physician, and the primary physician was contacted. Trends of aggregate AM use among hospitalized patients, measured as days of therapy (DoT), 26 months before (January 1, 2010-February 29, 2012) and 19 months after (March 1, 2012-September 30, 2013) the implementation of the program are reported. Antimicrobial use is normalized as DoT/1,000 patient-days (PD). Student\'s t-test was used to compare continuous variables. Trends of monthly antimicrobial use were analyzed using regression analysis. All tests were 2-tailed at the level of significance of 0.05. Analyses were performed using IBM SPSS software (Version 22; IBM Corp) and R (Version 3.0; R Core Team)

***Results.*** From 2010 monthly average AM (antibiotics, antifungal and antiviral agents) use declined from 697DoT/1,000PD to 592DoT/1,000PD (-15%*; p* \< 0.01). Antibiotic monthly use declined by 15% (630DoT/1,000PD to 537DoT/1,000PD*, p* \< 0.01). Of these, vancomycin showed the sharpest declined from 113 DoT/1,000PD to 90DoT/1,000PD (-20%*; p* \< 0.01). Monthly antifungal and antiviral use declined from 37DoT/1,000PD to 32DoT/1,000 PD (-13%; *p* = 0.08) and 26DoT/1,000PD to 19DoT/1,000 (27%; *p* = 0.01). Antimicrobial and antibiotic costs decreased from \$26,006/1,000 PD/year and \$16,080/1,000 PD/year (18% and 11% of all pharmacy drug costs) in 2011 to \$14,411/1,000 PD/year and 11,154 in 2013, respectively (9%; *p* \< 0.01, and 7%; *p* \< 0.01 of all pharmacy drug costs)

***Conclusion.*** Implementation of an integrated ASP with prospective audit with real time feedback to prescribers, led to a significant reduction of AM use and cost among hospitalized children
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